Axa
MCRB icon

Axa’s Seres Therapeutics MCRB Stock Holding History

Axa’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,065
Closed -$1.96M – 1238
2021
Q3 		$1.96M Buy
+14,065
New +$2.75M 0.01% 855
2020
Q3 		– Sell
-990
Closed -$94K – 1323
2020
Q2 		$94K Sell
990
-990
-50% -$86.9K ﹤0.01% 1208
2020
Q1 		$141K Sell
1,980
-3,750
-65% -$251K ﹤0.01% 1127
2019
Q4 		$395K Buy
+5,730
New +$425K ﹤0.01% 1025

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Axa's MCRB Position: Q4 2021 in Review

Axa sold out of Seres Therapeutics (MCRB) in Q4 2021, closing a stake of 14,065 shares — an estimated $1.96M sold.

Axa first reported a position in MCRB in Q4 2019 and held it in 4 quarters. The position peaked at $1.96M in Q3 2021. 148 funds tracked by Wall St. Rank hold MCRB as of Q4 2021.

  • Axa reported no remaining Seres Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Axa sold 14,065 Seres Therapeutics shares in Q4 2021, an estimated $1.96M.
  • Axa first reported a position in Seres Therapeutics in Q4 2019 and held it in 4 quarters.
  • Axa's Seres Therapeutics position peaked at $1.96M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2021.

Based on Axa's 13F filing for Q4 2021, filed 14 Feb 2022.